AACP New Investigator Award goes to Nadpara
VCU School of Pharmacy assistant professor Pramit Nadpara has received a 2017 American Association of Colleges of Pharmacy New Investigator Award.
Nadpara’s research interests include reporting health service use patterns and conducting health outcomes assessment studies with an emphasis in oncology.
“Although lung cancer in the elderly is associated with a poor prognosis,” Nadpara notes, “several treatment strategies can cure, or at least prolong, survival.”
With our aging population, he explains, it is critical to increase our understanding of the comparative effectiveness of lung cancer treatments in the elderly. His New Investigator Award research study will evaluate health outcomes associated with the duration of chemotherapy in older patients who have advanced non-small cell lung cancer. Non-small cell, the most common type of lung cancer, comprises about 85 percent of lung cancers.
Nadpara will receive $10,000 in start-up funding for his project. AACP’s New Investigator Award is designed to supplement independent research programs being conducted by early-career pharmacy faculty.
In 2014, Nadpara joined the School of Pharmacy’s Department of Pharmacotherapy and Outcomes Science, where he works within the Division of Pharmacoeconomics and Health Outcomes. He earned his Ph.D. in health outcomes research at West Virginia University, a master’s degree in pharmacy administration at St. John’s University and a bachelor’s degree in pharmacy at the University of Mumbai.
As one of 16 New Investigator Award recipients nationwide, Nadpara also will receive a $1,000 travel award to present his research findings at the 2018 AACP Annual Meeting in Boston.
Last fall, he and School of Pharmacy colleagues John Bucheit, Dave Dixon and Evan Sisson received an American College of Clinical Pharmacy Cardiology PRN Seed Grant to survey advanced practice practitioners on how they have adopted the 2013 ACC Cholesterol Guidelines. Other projects have included a Merck Sharpe and Dohme grant, along with Amy Pakyz, to study the epidemiology, risk factors and treatment for cancer patients with C. difficile infection.
Categories Faculty news, Research, Student news